The scientist fired from the British government’s Advisory Council on the Misuse of Drugs (ACMD) last year has launched a privately funded scientific committee to advise the public on the risks of drug use.
David Nutt, a psychopharmacologist from Imperial College in London, was dropped from the ACMD in October after his remarks contradicting the government’s classification of marijuana reached the press. Last month he announced the launch of his group, the Independent Scientific Committee on Drugs (ISCD). Continue reading Sacked drugs advisor launches private panel
This past July, the European Commission released estimates that if generic drugs were to enter markets immediately after patents expire—instead of the present average of seven months later—EU patients and national health services might save €3 billion ($4.5 billion) annually. But regulators acknowledge that costly and time-consuming patent disputes, and possible anticompetitive practices in the pharmaceutical industry, mean that such savings remain elusive. 